Aptorum Group (APM) has released an update.
Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the fiscal year 2023, down from $11.5 million in 2022, attributing the improvement to strict cost control and focusing on lead projects. The company also highlighted a proposed reverse merger with YOOV Group Holding, which upon completion would make YOOV a wholly-owned subsidiary, potentially boosting shareholder value. Cash reserves stood at $2.0 million at year-end, decreased from the previous year’s $5.0 million.
For further insights into APM stock, check out TipRanks’ Stock Analysis page.
